🔗 Share this article

As the US proceeds with unprecedented changes to its vaccine schedules, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has focused upon possible deaths after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Public health authorities were set to unveil sweeping changes to the childhood immunization program earlier this month, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with much of the global community with no evidence for benefit. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the division this year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US to become more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious experience in medication creation, oversight or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She is not an expert in industry regulation.”

Former directors of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who led CBER have had.”

The drug center has an immense portfolio at the FDA, she pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and more, and each of these must be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a major management element to the job, which oversees in excess of 5,000 staff members. “It is a massive leadership role, if you execute it properly,” Woodcock said.

Official Statement and Contentious Policies

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “questions stem from incorrect assumptions”.

“Her resume matches the responsibilities of her role,” the official said, pointing to the period Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's new expedited review system, a disputed rapid therapy clearance system that apparently worried her preceding directors. “How are these medications being chosen for this voucher program? Who is making the choices?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the agency looks to be trending towards laxer regulations of most medications, with the exception of shots.”

Documented Past Work on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, past, critics observe. She released a study using unverified crowd-sourced reports to assess the rate of myocarditis after Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the current government encompassed revising guidelines for new vaccines and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from getting COVID-19 vaccines.

“She’s an complete ideologue who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely misleading, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other skeptics, {like|